Compile Data Set for Download or QSAR
Report error Found 113 Enz. Inhib. hit(s) with all data for entry = 11785
TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647669(US20240025912, Compound 1-5 | 3-[(5S)-5-(3,5-diflu...)
Affinity DataEC50:  14.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647769(US20240025912, Compound 1-56 | (S)-5-(3,5-difluoro...)
Affinity DataEC50:  15.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647761(US20240025912, Compound 1-51 | (S)-3-(5-(3,5-diflu...)
Affinity DataEC50:  16.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647694(US20240025912, Compound 1-77 | (S)-5-(4-chloro-3,5...)
Affinity DataEC50:  16.7nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647724(US20240025912, Compound 4-9 | (S)-5-(3-fluoro-5-me...)
Affinity DataEC50:  17nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647690(US20240025912, Compound 1-75 | (S)-5-(4-chloro-3-f...)
Affinity DataEC50:  17.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647762(US20240025912, Compound 6-10 | 3-[(5S)-7-(S or R)-...)
Affinity DataEC50:  18.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647746((5S)-5-(3,5-difluorophenyl)-7-(S or R)- fluoro-2-(...)
Affinity DataEC50:  18.4nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647743(US20240025912, Compound 1-42 | (S)-2-(3-chlorobicy...)
Affinity DataEC50:  18.5nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647702(US20240025912, Compound 3-1 | 3-[(5S)-5-(3,5-diflu...)
Affinity DataEC50:  20nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647754(3-[(5S)-5-(3,5-difluorophenyl)-7-(S or R)-fluoro-3...)
Affinity DataEC50:  20.5nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647688(US20240025912, Compound 1-74 | (S)-5-(2,6-difluoro...)
Affinity DataEC50:  20.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647670(US20240025912, Compound 1-65 | (R)-3-(5-(3,5-diflu...)
Affinity DataEC50:  21.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647684(US20240025912, Compound 1-72 | (S)-5-(3-chloro-5-f...)
Affinity DataEC50:  21.2nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647661(US20240025912, Compound 1-1 | (5S)-2-(bicyclo[2.2....)
Affinity DataEC50:  21.6nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647675(US20240025912, Compound 1-8 | (5S)-2-(3-chlorobicy...)
Affinity DataEC50:  21.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647758(3-[(5S)-7-(S or R)-fluoro-3-oxo-5- phenyl-6,7-dihy...)
Affinity DataEC50:  21.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647750((5S)-7-(S or R)-fluoro-2-(3- fluorobicyclo[1.1.1]p...)
Affinity DataEC50:  21.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647663(US20240025912, Compound 1-2 | (5S)-5-(3,5-difluoro...)
Affinity DataEC50:  22.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647691(US20240025912, Compound 1-16 | (S)-2-(3-fluorobicy...)
Affinity DataEC50:  23.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647744(US20240025912, Compound 5-2 | (5S,7S)-5-(3,5-diflu...)
Affinity DataEC50:  25.7nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647715(US20240025912, Compound 1-28 | (5S)-2-[3- (difluor...)
Affinity DataEC50:  25.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647677(US20240025912, Compound 1-9 | (5S)-2-(3-fluorobicy...)
Affinity DataEC50:  26.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647727(US20240025912, Compound 1-34 | (5S)-2-[3-(1,1- dif...)
Affinity DataEC50:  26.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647692(US20240025912, Compound 1-76 | (S)-2-(3-fluorobicy...)
Affinity DataEC50:  27.5nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647686(US20240025912, Compound 1-73 | (S)-5-(3,5-difluoro...)
Affinity DataEC50:  28.2nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647707(US20240025912, Compound 1-24 | (S)-3-(5-(3-fluorop...)
Affinity DataEC50:  29.7nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647725(US20240025912, Compound 1-33 | (5S)-2-[3- (difluor...)
Affinity DataEC50:  30.4nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647667(US20240025912, Compound 1-4 | (5S)-2-(bicyclo[2.1....)
Affinity DataEC50:  31.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647705(US20240025912, Compound 1-23 | 3-[(5S)-5-(2-fluoro...)
Affinity DataEC50:  31.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647741(US20240025912, Compound 1-41 | (5S)-2-(3-chlorobic...)
Affinity DataEC50:  32.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647739(US20240025912, Compound 1-40 | (S)-5-(2,6-difluoro...)
Affinity DataEC50:  34nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647665(US20240025912, Compound 1-3 | (5S)-5-(3,5-difluoro...)
Affinity DataEC50:  34.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647723(US20240025912, Compound 1-32 | (5S)-2-[3-(1,1- dif...)
Affinity DataEC50:  36.4nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647721(US20240025912, Compound 1-31 | (5S)-2-[3- (difluor...)
Affinity DataEC50:  36.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647693(US20240025912, Compound 1-17 | 3-[(5S)-3-oxo-5-phe...)
Affinity DataEC50:  36.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647749(US20240025912, Compound 1-45 | (S)-5-(4-chlorophen...)
Affinity DataEC50:  37.7nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647699(US20240025912, Compound 1-20 | (5S)-5-(3,5-difluor...)
Affinity DataEC50:  38.5nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647740(US20240025912, Compound 4-17 | (5S,7S)-7-fluoro-2-...)
Affinity DataEC50:  38.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647751(US20240025912, Compound 1-46 | (S)-3-(5-(4-chlorop...)
Affinity DataEC50:  44nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647718(US20240025912, Compound 4-6 | (+-)-2-(3-fluorobicy...)
Affinity DataEC50:  44.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647706(US20240025912, Compound 3-3 | 2,2-difluoro-3-[(5S)...)
Affinity DataEC50:  45nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647771(US20240025912, Compound 1-58 | (S)-5-(3,5-difluoro...)
Affinity DataEC50:  45.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647737(US20240025912, Compound 1-39 | 4-[(5S)-3-oxo-5-phe...)
Affinity DataEC50:  47nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647683(US20240025912, Compound 1-12 | (5S)-5-(3,5-difluor...)
Affinity DataEC50:  49.1nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647720(US20240025912, Compound 4-7 | (S)-3-(3-oxo-5-(p-to...)
Affinity DataEC50:  49.5nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647729(US20240025912, Compound 1-35 | 4-[(5S)-5-(3,5-difl...)
Affinity DataEC50:  49.7nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647671(US20240025912, Compound 1-6 | (5S)-2-(3-fluorobicy...)
Affinity DataEC50:  51.2nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647716(US20240025912, Compound 4-5 | (+-)-5-(2,3-difluoro...)
Affinity DataEC50:  53.8nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM647772(US20240025912, Compound 1-59 | (S)-2-(3-chlorobicy...)
Affinity DataEC50:  53.9nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

Displayed 1 to 50 (of 113 total ) | Next | Last >>
Jump to: